Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-01-25
2005-01-25
Low, Christopher S. F. (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S003100, C514S012200, C530S303000, C530S324000
Reexamination Certificate
active
06846800
ABSTRACT:
Methods for treating a patient for insulin resistance to decrease the insulin resistance in a patient having Metabolic Syndrome comprising Primary Insulin Resistance and abdominal/visceral obesity comprise administering to the patient growth hormone or a functional derivative thereof in an amount effective for decreasing insulin resistance of the patient.
REFERENCES:
patent: 5268277 (1993-12-01), Grandi et al.
patent: 5426096 (1995-06-01), Sonksen et al.
Johansson et al., “Growth Hormone-Deficient Adults are Insulin-Resistant” Metabolism, vol. 44, No. 9, pp 1126-1129, 1995.*
Holly etal., J. Endocr., vol. 118, pp. 353-364, 1988.*
Salomon et al., N. Engl. J. Med., vol. 321, No. 26, pp. 1797-1803, Dec. 28, 1989.*
Per Björntorp, “Visceral Obesity: A ‘Civilization Syndrome’,”Obesity Research, vol. 1, No. 3, May 1993, pp. 206-221.
Gerald M. Reaven, “Role of Insulin Resistance in Human Disease,”Diabetes, vol. 37, Dec. 1988, pp. 1595-1607.
B-Å Bengtsson, “The Consequences of Growth Hormone Deficiency in Adults,”Acta Endrocrinological, 128 Suppl. 2: 2-5, 1993, pp. 2-5.
Gerald M. Reaven, “Pathophysiology of Insulin Resistance in Human Disease,”Physiological Review, vol. 75, No. 3, Jul. 1995, pp. 473-486.
Salomon, F., et al., “The Effects of Treatment with Recombinant Human Growth Hormone on Body Composition and Metabolism in Adults with Growth Hormone Deficiency,”The New England Journal of Medicine, vol. 321, No. 26, Dec. 28, 1989, pp. 1797-1803.
Johansson, Jan-Ove, et al., “Growth Hormone—Deficient Adults are Insulin-Resistant,”Metabolism, vol. 44, No. 9, Sep. 1995, pp. 1126-1129.
Rosén, Thord, et al., “Cardiovascular Risk Factors in Adult Patients with Growth Hormone Deficiency,”Acta Endocrinologica, 1993, vol. 129 pp. 195-200.
Johansson, Jan-Ove, et al., “High Fibrinogen and Plasminogen Activator Inhibitor Activty in Growth Hormone-Deficient Adults,”Arteriosclerosis and Thrombosis, vol. 14, No. 3, Mar. 1994, pp. 434-437.
Markussis, Viron, et al., “Detection of Premature Atherosclerosis by High-Resolution Ultrasonography in Symptom-Free Hypopituitary Adults,”The Lancet, vol. 340, Nov. 14, 1992, pp. 1188-1192.
Mårin, P., et al., “Endocrine-Metabolic Pattern and Adipose Tissue Distribution,”Hom Res, 39 (suppl 3), 1993, pp. 81-85.
Rosén, Thord, and Bengtsson, Bengt-Åke, “Premature Mortality Due to Cardiovascular Disease in Hypopituitarism,”The Lancet, vol. 336, Aug. 4, 1990, pp. 285-288.
Mårin, P., et al., “Cortisol Secretion in Relation to Body Fat Distribution in Obese Premenopausal Women,”Metabolism, vol. 41, No. 8, Aug. 1992, pp. 882-886.
Mårin, P., et al., “Low Concentrations of Insulin-Like Growth Factor-I in Abdominal Obesity,”International Journal of Obesity, vol. 17, 1993, pp. 83-89.
Mårin, P., et al., “Androgen Treatment of Abdominally Obese Men,”Obesity Research, vol. 1, No. 4, Jul. 1993, pp. 245-251.
Veldhuis, J.D., et al., “Differential Impact of Age, Sex Steroid Homones, and Obesity on Basal Versus Pulsatile Growth Hormone Secretion in Men as Assessed in an Ultrasensitive Chemiluminescence Assay,”Journal of Clinical Endocrinology and Metabolism, vol. 80, No. 11, 1995, pp. 3209-3222.
Hartman, M.L., et al., “A Low Dose Euglycemic Infusion of Recombinant Human Insulin-Like Growth Factor I Rapidly Suppresses Fasting-Enhanced Pulsatile Growth Hormone Secretion in Humans,”J. Clin. Invest., vol. 91, Jun. 1993, pp. 2453-2462.
De Boer, H., et al., “Clinical Aspects of Growth Hormone Deficiency in Adults,”Endocrine Reviews, vol. 16, No. 1, 1995, pp. 63-86.
Landin-Wilhelmsen, K., et al., “Serum Insulin-Like Growth Factor I in a Random Population Sample of Men and Women: Relation to Age, Sex, Smoking Habits, Coffee Consumption and Physical Activity, Blood Pressure and Concentrations of Plasma Lipids, Fibrinogen, Parathyroid Hormone and Osteocalcin,”Clinical Endocrinology, vol. 41, 1994, pp. 351-357.
Kvist, H., et al., “Apiose Tissue Volume Determination in Males by Computed Tomography and40K,”International Journal of Obesity, vol. 12, 1988, pp. 249-266.
Chowdhury, B., et al., “A Multicompartment Body Composition Technique Based on Computerized Tomography,”International Journal of Obesity, vol. 18, 1994, pp. 219-234.
Lipoprotein Analysis A Practical Approach, C.A. Converse and E.R. Skinner, eds., Oxford University Press, New York, New York, 1992, pp. ix-xv.
Dole, V.P., and Meinertz, H., “Microdetermination of Long-Chain Fatty Acids in Plasma and Tissues,”The Journal of Biological Chemistry, vol. 235, No. 9, Sep. 1960, pp. 2595-2599.
Friberger, P., et al., “Methods for Determination of Plasmin, Antiplasmin and Plasminogen by Means of Substrate S-2251,”Haemostasis, vol. 7, 1978, pp. 138-145.
Larsson, Bo, et al., “Obesity, Adipose Tissue Distribution and Health in Men—The Study of Men Born in 1913,”Appetite, vol. 13, 1989, pp. 37-44.
Marcus, R., et al., “Effects of Short Term Administration of Recombinant Human Growth Hormone to Elderly People,”Journal of Clinical Endocrinology and Metabolism, vol. 70, No. 2, pp. 519-527.
Rudman, D., et al., “Effects of Human Growth Hormone in Men Over 60 Years Old,”The New England Journal of Medicine, vol. 323, No. 1, Jul. 5, 1990, pp. 1-6.
Bengtsson, B-Å, et al., “Treatment of Adults with Growth Hormone (GH) Deficiency with Recombinant Human GH,”Journal of Clinical Endocrinology and Metabolism, vol. 76, No. 2, 1993, pp. 309-317.
Rosenbaum, M., et al., “Effects of Systemic Growth Hormone (GH) Administration on Regional Adipose Tissue Distribution and Metabolism in GH-Deficient Children,”Journal of Clinical Endocrinology and Metabolism, vol. 69, No. 6, 1989 pp. 1274-1281.
Bolli, G.B., and Gerich, J.E., “The ‘Dawn Phenomen’—A Common Occurrence in Both Non-Insulin-Dependent and Insulin-Dependent Diabetes Mellitus,”The New England Journal of Medicine, vol. 310, No. 2, Mar. 22, 1984, pp. 746-750.
Fowelin, J., et al., “Combined Effect of Growth Hormone and Cortisol on Late Posthypoglycemic Insulin Resistance in Humans,”Diabetes, vol. 38, Nov. 1989, pp. 1357-1364.
Fowelin, J., et al., “Effects of Treatment with Recombinant Human Growth Hormone on Insulin Sensitivity and Glucose Metabolism in Adults with Growth Hormone Deficiency,”Metabolism, vol. 42, No. 11, Nov. 1993, pp. 1443-1447.
DeFronzo, R.A., et al., “Effects of Insulin on Peripheral and Splanchnic Glucose Metabolism in Noninsulin-Dependent (Type II) Diabetes Mellitus,”J. Clin. Invest., vol. 76, Jul. 1985, pp. 149-155.
Lund, S., et al., “Comparative Effects of IGF-I and Insulin on the Glucose Transporter System in Rat Muscle,” 1994 the American Physiological Society, pp. E461-E466.
Ayling, C.M., et al., “Human Growth Hormone Treatment of Hypophysectomized Rats Increases the Proportion of Type-1 Fibres in Skeletal Muscle,”Journal of Endocrinology, vol. 123, 1989, pp. 429-435.
Rudling, M., et al., “Importance of Growth Hormone for the Induction of Hepatic Low Density Lipoprotein Receptors,”Proc. Natl. Acad. Sci. USA, vol. 89, Aug. 1992, pp. 6983-6987.
Bo Angelin and Mats Rudling, “Growth Hormone and Hepatic Lipoprotein in Metabolism,”Current Opinion in Lipidology, vol. 5, 1994, pp. 160-165.
Elam, M.B., et al., “In Vitro Growth Hormone Treatment Stimulates Secretion of Very Low Density Lipoprotein by the Isolated Perfused Rat Liver,”Endocrinology, vol. 131, No. 6, pp. 2717-2722.
Richelsen, B., et al., “Growth Hormone Treatment of Obese Women for 5 wk: Effect on Body Composition and Adipose Tissue LPL Activity,” The American Physiology Society, 1994, pp. E211-E216.
Reaven, G.M., et a
Bengtsson Bengt-Åke
Björntorp Per
Johannsson Gudmundur
Lönn Lars
Märin Per
Dinsmore & Shohl LLP
Low Christopher S. F.
Mohamed Abdel A.
Pharmacia AB
LandOfFree
Method for treating a patient having metabolic syndrome does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating a patient having metabolic syndrome, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating a patient having metabolic syndrome will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3396765